Stockreport

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoRx, Inc.  (RNXT) 
PDF RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of [Read more]